When does the Pulmozyme (dornase alfa) patent expire?
DrugPatentWatch does not list a specific “Pulmozyme patent expiry” date in the information available to it, so there is no single confirmed expiration date to cite from that source [1]. Patent expiry for biologics and biologic-like products can also vary by jurisdiction and by which specific patent is being considered (for example, composition, formulation, method-of-use, or process patents), so the controlling date depends on the exact patent family and country.
What patents affect Pulmozyme’s effective market exclusivity?
For drugs like Pulmozyme (dornase alfa), the end of “patent protection” and the end of “market exclusivity” may not match. Even after one patent expires, other patents can still block competitors through litigation or continued exclusivity protections, which is why an exact “expiry date” needs the specific patent(s) and territory to be identified.
How can you find the exact expiry date for your country?
To get the accurate expiry for Pulmozyme in a specific market (e.g., US, EU, UK, or another country), you need:
1) the patent family number(s) and country/region, and
2) which patent claim is being used to block entry (not just the earliest filing date).
DrugPatentWatch is typically used to pull those patent-family details for a given product and territory [1].
Source
[1] https://www.drugpatentwatch.com/